ERBB2 and cancer: Similarly, IGF1R inhibition in combination with EGFR inhibition in EGFR over-expressing cancer cells or IGF1R inhibition in combination with HER2 inhibition in HER2 positive cancer cells have also shown improved results over the use of single agents only [96,97,98].